 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...90919293949596979899100...235236» |
- | leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Journal: Comparison of weekly methotrexate regimen versus methotrexate folinic acid 8-day regimen for treatment of low-risk gestational trophoblastic neoplasia. (Pubmed Central) - May 26, 2022
MTX-FA 8-day regimen is more effective than weekly MTX regimen in the first line treatment of low-risk GTN including patients even with higher FIGO risk scores. Treatment resistance may develop especially in patients with lung metastasis.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Journal, Adverse events, HEOR: Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study. (Pubmed Central) - May 26, 2022
This real-world study demonstrated AE burden in alignment with previous clinical studies. Regardless of regimen used, AEs are associated with substantial healthcare costs due to inpatient care.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Observational data, Retrospective data, Journal, Real-world evidence: Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer. (Pubmed Central) - May 26, 2022
Regardless of regimen used, AEs are associated with substantial healthcare costs due to inpatient care. Real-world data revealed that all three antiangiogenic drugs were used as second-line therapy after first-line anti-EGFR antibodies and showed similar treatment durations.
- |||| Enrollment open: MORPHEUS-PDAC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) (clinicaltrials.gov) - May 25, 2022
P1/2, N=290, Recruiting, Sponsor: Hoffmann-La Roche
Real-world data revealed that all three antiangiogenic drugs were used as second-line therapy after first-line anti-EGFR antibodies and showed similar treatment durations. Active, not recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Biomarker, Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Liquid biopsy, Biopsy: PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - May 24, 2022
P2, N=31, Terminated, Sponsor: Judith Dixon-Hughes
Active, not recruiting --> Recruiting N=278 --> 31 | Trial completion date: Dec 2023 --> Aug 2021 | Recruiting --> Terminated | Trial primary completion date: Jan 2023 --> Aug 2021; Due to funding being withdrawn
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open, Metastases: Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - May 23, 2022
P3, N=426, Recruiting, Sponsor: Sun Yat-sen University
N=278 --> 31 | Trial completion date: Dec 2023 --> Aug 2021 | Recruiting --> Terminated | Trial primary completion date: Jan 2023 --> Aug 2021; Due to funding being withdrawn Not yet recruiting --> Recruiting
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., Avastin (bevacizumab) / Roche
After analyzing various treatments for metastatic CRC, researchers zeroed in on FOLFIRI + bevacizumab. https://t.co/VY4p5ZROiW #CRCSM (Twitter) - May 23, 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical: @RachelRiechelm2 comenta os resultados do fase III ACHIEVE, um dos 6 estudos prospectivos que exploraram se 3 meses de terapia ADJ com FOLFOX ou CAPOX é não inferior a 6 meses de tto em pts com CA cólon estágio III curativamente ressecado - https://t.co/O48uMExwOo (Twitter) - May 23, 2022
- ||| leucovorin calcium / Generic mfg.
One theory is that leucovorin can compete with free MTX, not the glutamate MTX ( latter preferentially present in neoplastic cells ) (Twitter) - May 23, 2022
- ||| leucovorin calcium / Generic mfg.
Clinical: We do <0.1 with outpatient oral leucovorin. If they are <0.05 then they don't need the oral leucovorin unless they are delayed clearance. (Twitter) - May 23, 2022
- ||| leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Clinical: Does your institution discharge patients at 0.05 or 0.1 levels of methotrexate? Also outpatient Rx for oral leucovorin? (Twitter) - May 23, 2022
- |||| leucovorin calcium / Generic mfg.
Clinical, Pleural effusion: If the patient does have pleural effusion or ascites should we use folinic acid for longer period of time or what’s the approach in such cases? (Twitter) - May 23, 2022
- ||| leucovorin calcium / Generic mfg.
Folinic acid is antidote of MTX TOXICITY. WHILE folic acid is used in anemia both are different drugs. (Twitter) - May 23, 2022
- ||| leucovorin calcium / Generic mfg.
Nomorgrams estimate time-dependent⬇️MTX Predicts impending toxicity. Glucarpidase = Recombinant bacterial carboxypeptidase Cleaves MTX = DAMPA + glutamate ⬇️plasma MTX 97% in 15 min No effect intracellular MTX so continue leucovorin! LV substrate for GP administer 2 hrs after (Twitter) - May 22, 2022
- |||| methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg.
Protocol Admission Urine alkalization with NaHCO3 (150 mEq in 1 L) Wait for urine pH>7 Rx high dose MTX Leucovorin* (LV) rescue 24 hours later Monitor MTX levels daily *LV doesn't cross BBB and rescues body from toxicity. LV works without DHFR (which is inhibited by MTX) (Twitter) - May 22, 2022
- |||| leucovorin calcium / Generic mfg.
Leucovorin Discovered as growth factor for bacterium Leuconostoc citrovorum (1948) LV converted to reduced folic acid (FH4) Does not require DHFR for its function! LV allows for some purine/pyrimidine synthesis to occur even in presence of DHFR inhibition Does not cross BBB (Twitter) - May 22, 2022
- |||| methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg.
High Dose Methotrexate - Tweetorial The Players! MTX (>500 mg/m2) Leucovorin (folinic acid) Sodium bicarbonate Glucarpidase (hopefully not!) How we make thymidylate (dTMP) FH2+NADH = FH4 via dihydrofolate reductase (DHFR) dUMP+FH4 = dTMP via thymidylate synthase (TS) (Twitter) - May 22, 2022
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Biliary-Related Events (BREs) in Pancreatic Cancer (PC) Patients (Pts) (Livestream Frontenac, CC, 1st Floor) - May 22, 2022 - Abstract #MASCCISOO2022MASCC_ISOO_290;
Methods Retrospective evaluation of BREs in patients treated with FOLFIRINOX or Gemcitabine based treatments,in adjuvant and locally advanced settings at our Institution; from January 2016 to July 2020.SPSS was used for data analysis...Md follow-up time of 21months(m; [21.6-30.3],21 deaths seen(66%).The md overall survival (OS) of the population was 15m(8.7-21.3).A shorter OS related to BREs during chemotherapy(20vs11m,p=0.018) and hospital admissions(24vs9m,p=0.004).Biliary stent prior to starting chemotherapy associated to a shorter OS (p=0.846). Conclusions BREs lead to multiple hospital admissions, increasing mortality in PC Pts.Prophylactics strategies, such as antibiotics have been proposed in previous trials.Prospective studies are warranted.
- || spartalizumab (PDR001) / Novartis
P2 data, Clinical Trial,Phase II, Journal, Combination therapy: Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). (Pubmed Central) - May 21, 2022
P2
Currently, no trials have investigated the impact of immunotherapy in combination with FLOT chemotherapy as perioperative treatment for resectable gastric or GEJ adenocarcinoma. Some studies have suggested a change in the tumor immune micro-environment following neoadjuvant chemotherapy in this setting, reinforcing the relevance to propose a phase II trial evaluating efficacy and safety of Spartalizumab in combination with perioperative chemotherapy, with the aim of improving treatment efficacy and survival outcomes.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical protocol, Journal: Treatment of unresectable locally advanced pancreatic cancer with percutaneous irreversible electroporation (IRE) following initial systemic chemotherapy (LAP-PIE) trial: study protocol for a feasibility randomised controlled trial. (Pubmed Central) - May 21, 2022
Results will be presented to international conferences with an interest in oncology, hepatopancreaticobiliary surgery and interventional radiology and be published in a peer-reviewed journal. ISRCTN14986389.
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Circulating tumor DNA: Just talked ē @doctorC369. Also 📟@aparna1024 for the @SU2C #ctDNA FOLFIRI arm. 💡You are essentially treating ➕micrometastatic disease. Triplets used in advanced non-metastatic. In essence it would be similar.@NRGonc @ALLIANCE_org has endorsed the approach. So why won’t we? 💭 (Twitter) - May 21, 2022
- || Clinical, Journal: Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing 1st-line chemotherapy with FOLFIRINOX or Gemcitabine/nab-paclitaxel. (Pubmed Central) - May 20, 2022
Patients with aPC undergoing palliative first-line chemotherapy with FOLFIRINOX or GN face a high risk for VTE/ATE and its diagnosis is linked to worse clinical outcomes. VTE-risk prediction models have limited ability to sub-stratify thrombotic events in this high-risk scenario.
- || Clinical, Journal, Real-world evidence: First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort. (Pubmed Central) - May 20, 2022
Based on population-based data in patients with metastatic PDAC, treatment predominantly consists of FOLFIRINOX in the first line and gemcitabine with or without nab-paclitaxel in the second line. FOLFIRINOX in the first line shows superior OS compared with gemcitabine with or without nab-paclitaxel.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical, Reimbursement: Love this trial. But did your site have any problems with reimbursement for Irinotecan in stage 3 patients? FOLFIRINOX adjuvant not in any guideline, Irinotecan not provided by study, our site is held up while financial people try to figure out who reimburses this? (Twitter) - May 20, 2022
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal: Curative resection after chemotherapy and chemoradiotherapy for postoperative recurrence of pancreatic tail cancer in the abdominal wall: a case report. (Pubmed Central) - May 20, 2022
FOLFIRINOX in the first line shows superior OS compared with gemcitabine with or without nab-paclitaxel. Long-term survival could be achieved by radical resection with sufficient surgical margins for recurrence of PDAC in the abdominal wall if new other recurrent lesions, including peritoneal dissemination, are prevented through chemotherapy.
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Reimbursement, Circulating tumor DNA: Agreed for stage IV CRC. but for a person dx with stage 3 with NED except positive ctDNA I would have thought FOLFIRINOX would still be considered experimental? I have a feeling when you do the peer to peer that is how insurance will see it, but who knows. (Twitter) - May 20, 2022
- ||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
I personally would have called it 🇺🇸FOLFOXIRI (2400 mg/m2; not the European version 3200 mg/m2) since it’s for #colorectalcancer as opposed to modified FOLFIRINOX. Essentially with all the modifications, they are now virtually the same. FOLFOXIRI for #CRCSM. Very reasonable. ✅ (Twitter) - May 20, 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Reimbursement, Circulating tumor DNA: Thanks! It is a great study, I hope the insurance companies see it the same way. If I understand, you are saying those in Arm 4 with positive ctDNA have recurrent dz so we should get insurance reimbursement to treat with FOLFIRINOX as for high risk stage IV? (Twitter) - May 20, 2022
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Thanks for bring that up. We received this feedback and national PIs are working on a letter to address this matter which will hopefully help to get approval of Irinotecan for its use in interventional arm (FOLFIRINOX) ✳️There is great national uptake for this study 🤞 (Twitter) - May 20, 2022
- ||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Clinical: With you on this. A typical regimen for me is 8 cycles of FOLFOX or 4 of Gem/Abraxane followed by restaging. PET imaging isn't routine for us but I repeat if it was done initially. I also exclude patients with duodenal wall involvement from EGD/EUS. (Twitter) - May 20, 2022
- ||| Onivyde (nanoliposomal irinotecan) / Ipsen
New P1 trial: SIRACUSA: A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas (clinicaltrials.gov) - May 20, 2022
P1, N=88, Not yet recruiting, Sponsor: Ipsen
- ||| levoleucovorin calcium / Generic mfg., leucovorin calcium / Generic mfg.
https://t.co/nyS35eoYah Basically Pfizer stopped making it and the other generic manufacturers won’t tell why they don’t have it Another cabal like they did for leucovorin to get people to use expensive Fusilev ? (Twitter) - May 19, 2022
- leucovorin calcium / Generic mfg., sulphadiazine / Generic mfg.
THE SEQUELAE OF CONGENITAL TOXOPLASMOSIS – HOW FREQUENT? HOW SEVERE? () - May 19, 2022 - Abstract #ESPID2022ESPID_1373;
CT was confirmed in 43 (14.9%) of which 37 (86%) presented sequelae at the end of follow up. 33 patients presented scars at fundoscopy (19 on macular area) and 24 with Central nervous system (CNS) manifestations (9 hydrocephalus, 18 CNS calcifications, 6 epilepsy, 8 microcephaly), and one child died during the follow up.
- OCULAR LESIONS IN AN ADOLESCENT – A CHALLENGING DIAGNOSIS () - May 19, 2022 - Abstract #ESPID2022ESPID_950;
Learning Points/ Congenital toxoplasmosis may present at a later age and physicians should have a high level of suspicion. Adequate and timely treatment is paramount to minimize the risk of lifelong sight-threatening lesions.
- PERSISTENT NEUTROPENIA DUE TO CONGENITAL TOXOPLASMOSIS TREATMENT () - May 19, 2022 - Abstract #ESPID2022ESPID_949;
He started pyrimethamine(1mg/kg/day), sulfadiazine(100mg/kg/day) and folinic acid(15mg/day, 3 times a week). Neutropenia (570neutrophils/mm3 ) was detected 7 weeks after treatment initiation.
- leucovorin calcium / Generic mfg., sulphadiazine / Generic mfg., pyrimethamine / Generic mfg.
CONGENITAL TOXOPLASMOSIS: PREVENTION IS THE KEY () - May 19, 2022 - Abstract #ESPID2022ESPID_929;
Learning Points/ This case underlines the importance of surveillance and screening programs for pregnant women, and how a multidisciplinary approach between pediatricians and gynecologists might be important to reduce the risk of vertical transmission. It also highlights the importance of early diagnosis and treatment, in order to reduce morbidity.
- leucovorin calcium / Generic mfg., sulphadiazine / Generic mfg., pyrimethamine / Generic mfg.
CONGENITAL TOXOPLASMOSIS IN TWINS: CASE REPORT () - May 19, 2022 - Abstract #ESPID2022ESPID_928;
The diagnosis and treatment in twin pregnancies does not differ from singleton pregnancies. Prevention of primary infection during susceptible pregnancies is essential
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial primary completion date, IO biomarker: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma (clinicaltrials.gov) - May 19, 2022
P2, N=40, Recruiting, Sponsor: University of Kansas Medical Center
Prevention of primary infection during susceptible pregnancies is essential Trial primary completion date: Apr 2022 --> Apr 2023
- || Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
Clinical, Journal: Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer. (Pubmed Central) - May 19, 2022
However, some discrepancies between solid and liquid biopsies have been observed. These results suggest a need to improve accuracy of RAS analyses, especially in solid biopsies.
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
P2 data, Clinical Trial,Phase II, Journal: Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer. (Pubmed Central) - May 18, 2022
These results suggest a need to improve accuracy of RAS analyses, especially in solid biopsies. NAM/GEM/S-1 therapy is safe and could be promising option for unresectable pancreatic cancer, especially for stage IV cancer.
- |||| Yidafan (ivonescimab) / Akesobio, Summit Therapeutics, ligufalimab (AK117) / Akesobio
New P2 trial: AK112-206: A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer (clinicaltrials.gov) - May 18, 2022
P2, N=114, Not yet recruiting, Sponsor: Akeso
- ||| ASP3082 / Astellas
New P1 trial: 3082-CL-0101: A Study of ASP3082 in Adults With Advanced Solid Tumors (clinicaltrials.gov) - May 18, 2022
P1, N=136, Not yet recruiting, Sponsor: Astellas Pharma Inc
- | leucovorin calcium / Generic mfg.
Journal: A Case of UFT/LV-Induced Acute Liver Failure after Surgery for Sigmoid Colon Cancer (Pubmed Central) - May 18, 2022
Oral uracil and tegafur plus Leucovorin(UFT/LV)therapy is one of the standard adjuvant chemotherapies for colorectal cancer, and is widely used without any serious adverse events...Two months later, the platelet count decreased markedly, but fortunately, no bleeding occurred. There has been no recurrence since 2 years after the surgery without any additional adjuvant therapy.
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Metastases: Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (clinicaltrials.gov) - May 18, 2022
P1, N=52, Recruiting, Sponsor: M.D. Anderson Cancer Center
There has been no recurrence since 2 years after the surgery without any additional adjuvant therapy. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022
- | Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion date: mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer (clinicaltrials.gov) - May 18, 2022
P2, N=119, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2021 --> Dec 2022 Trial completion date: Feb 2022 --> Jun 2022
- ||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion, Trial primary completion date: NALIRICC: Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (clinicaltrials.gov) - May 18, 2022
P2, N=100, Completed, Sponsor: AIO-Studien-gGmbH
Trial completion date: Feb 2022 --> Jun 2022 Recruiting --> Completed | Trial primary completion date: Sep 2021 --> Dec 2021
- ||| Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Trial primary completion date: INTEGA: Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (clinicaltrials.gov) - May 18, 2022
P2, N=97, Completed, Sponsor: AIO-Studien-gGmbH
Recruiting --> Completed | Trial primary completion date: Sep 2021 --> Dec 2021 Active, not recruiting --> Completed | Trial primary completion date: Oct 2021 --> Mar 2022
- | Trial completion, Trial completion date, Metastases: GEMPAX: Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - May 18, 2022
P3, N=211, Completed, Sponsor: UNICANCER
Active, not recruiting --> Completed | Trial primary completion date: Oct 2021 --> Mar 2022 Active, not recruiting --> Completed | Trial completion date: Oct 2022 --> Apr 2022
- | Biomarker, Trial completion date, Trial primary completion date, Metastases: PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - May 18, 2022
P2, N=500, Recruiting, Sponsor: Judith Dixon-Hughes
Active, not recruiting --> Completed | Trial completion date: Oct 2022 --> Apr 2022 Trial completion date: Nov 2023 --> Jan 2026 | Trial primary completion date: Sep 2021 --> Dec 2025